Cargando…

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers

Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated in CRC. Targeting the downstream substrate MEK in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Temraz, Sally, Mukherji, Deborah, Shamseddine, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613347/ https://www.ncbi.nlm.nih.gov/pubmed/26404261 http://dx.doi.org/10.3390/ijms160922976

Ejemplares similares

Potential Targets for Colorectal Cancer Prevention
por: Temraz, Sally, et al.
Publicado: (2013)

Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions
por: Kreidieh, Malek, et al.
Publicado: (2020)

Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer
por: Temraz, Sally, et al.
Publicado: (2019)

Exosomal Non Coding RNA in LIQUID Biopsies as a Promising Biomarker for Colorectal Cancer
por: Baassiri, Amro, et al.
Publicado: (2020)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Trends in lung cancer incidence in Lebanon by gender and histological type over the period 2005–2008
por: Temraz, Sally, et al.
Publicado: (2017)

Inflammatory Markers and MicroRNAs: The Backstage Actors Influencing Prognosis in Colorectal Cancer Patients
por: Nasr, Rihab, et al.
Publicado: (2018)

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
por: Rittler, Dominika, et al.
Publicado: (2020)

The Crosstalk between Microbiome and Immune Response in Gastric Cancer
por: Nasr, Rihab, et al.
Publicado: (2020)

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
por: Lionetti, Marta, et al.
Publicado: (2015)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014)

Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature
por: El Dika, Imane, et al.
Publicado: (2014)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023)

The unveiling of a new risk factor associated with bladder cancer in Lebanon
por: Temraz, Sally, et al.
Publicado: (2019)

Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome
por: Temraz, Sally, et al.
Publicado: (2021)

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
por: Jokinen, Elina, et al.
Publicado: (2012)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

Mitochondrial Respiration in KRAS and BRAF Mutated Colorectal Tumors and Polyps
por: Rebane-Klemm, Egle, et al.
Publicado: (2020)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
por: Zhou, XuSha, et al.
Publicado: (2021)

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
por: Yokota, Tomoya
Publicado: (2012)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer
por: Yamasaki, Juntaro, et al.
Publicado: (2022)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction
por: Tian, Sun, et al.
Publicado: (2013)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis
por: Muranushi, Hiroyuki, et al.
Publicado: (2022)

Cancer trends in Lebanon: a review of incidence rates for the period of 2003–2008 and projections until 2018
por: Shamseddine, Ali, et al.
Publicado: (2014)

Primary synovial sarcoma of the kidney: a case report of complete pathological response at a Lebanese tertiary care center
por: El Chediak, Alissar, et al.
Publicado: (2018)

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
por: Haibe, Yolla, et al.
Publicado: (2020)

The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges
por: Bouferraa, Youssef, et al.
Publicado: (2021)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis
por: Madala, Satish K., et al.
Publicado: (2014)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
por: Popovici, Vlad, et al.
Publicado: (2013)

Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations
por: Li, Wenbin, et al.
Publicado: (2015)

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
por: Huang, Chi-Jung, et al.
Publicado: (2016)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
por: Won, Daeyoun David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6grbq1lm74smrh8bcjga0f8icf